Arbutus Receives Regulatory Approval to Initiate a Phase 1a/1b Clinical Trial with AB-836, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Infection

Source :: GlobeNewswire. March 16, 2021
Publication Year :: 2021
Abstract: WARMINSTER, Mar 16, 2021 (GLOBE NEWSWIRE via COMTEX) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B [...]

Subjects :: Arbutus Biopharma Corp. -- Product development
Infection -- Drug therapy
Hepatitis B -- Drug therapy
Clinical trials -- Health aspects
Coronaviruses -- Health aspects
Pharmaceutical industry -- Product development
Banking, finance and accounting industries
Business

Tools